Provyx vs. IQVIA OneKey: Provider Data Compared

IQVIA OneKey

Founded 2016 (IMS Health + Quintiles merger) · Durham, NC · Public (NYSE: IQV), ~$45B market cap

What IQVIA OneKey Offers

IQVIA is not a simple data vendor. It's a $15 billion healthcare data and analytics company formed from the 2016 merger of IMS Health and Quintiles. Their product suite spans clinical trial management, real-world evidence, commercial analytics, and technology platforms that serve the largest pharma and life sciences organizations in the world. OneKey is one piece of that ecosystem, but it's deeply embedded in it.

OneKey, which IQVIA acquired when it was known as SK&A, is a healthcare professional (HCP) and healthcare organization (HCO) reference database. According to IQVIA's website, OneKey covers approximately 9 million healthcare professionals globally across more than 80 countries. That global footprint is a genuine differentiator. If your sales team operates across the EU, Asia-Pacific, and Latin America, very few databases can match that reach.

The core of OneKey is provider identity resolution. IQVIA assigns each healthcare professional a unique identifier and links that professional to their organizational affiliations, specialties, and geographic locations. For pharma companies running multi-channel commercial campaigns, this identity layer matters because it connects prescribing behavior to individual providers. When your field reps visit a physician, your digital team emails that same physician, and your managed markets team engages the health system where they practice, the OneKey ID ties all of those interactions to a single profile. That's harder to replicate than it sounds.

And that's where IQVIA's real strength lives: prescribing data. Through their proprietary data assets, IQVIA can tell you which physicians are writing scripts for specific drug classes, how prescribing volumes trend over time, and how your product stacks up against competitors at the individual prescriber level. No other vendor offers this at IQVIA's scale. It's the reason large pharma companies pay what they pay. For a brand manager at a top-20 pharma company, knowing that Dr. Smith wrote 47 prescriptions for a competing drug last quarter is the kind of intelligence that directly shapes territory strategy and call planning.

IQVIA's data sourcing is also distinct from most competitors. They combine proprietary physician surveys, pharmacy claims data, hospital discharge records, and commercial databases to build their provider profiles. This multi-source approach gives them data points that public registries simply don't contain, particularly around prescribing behavior, patient panel size estimates, and clinical activity indicators. The tradeoff is that this proprietary sourcing makes it harder for customers to independently verify the underlying data.

Beyond OneKey, IQVIA offers analytics platforms, real-world evidence studies, clinical trial design and recruitment, and consulting services. Their technology stack includes the Orchestrated Customer Engagement (OCE) platform for commercial teams, which integrates CRM functionality with their data assets. For a large pharma commercial organization, this integration between data, analytics, and execution tools can be genuinely valuable. You're not just buying a database; you're buying into an ecosystem where your CRM, your analytics dashboards, and your provider data all speak the same language.

IQVIA also maintains strong compliance frameworks. They're experienced in navigating healthcare data regulations across multiple jurisdictions, including GDPR in Europe and various state-level privacy laws in the U.S. For enterprise buyers with legal teams that scrutinize every vendor, IQVIA's compliance posture is a meaningful advantage. They've been through thousands of enterprise procurement reviews, and their security documentation and data processing agreements reflect that experience.

On G2, OneKey holds approximately a 4.0 rating. Reviewers frequently praise the depth of data and the global coverage. The most common complaints center on platform complexity, long onboarding timelines, and cost. Several reviewers note that getting value from IQVIA requires dedicated internal resources to manage the relationship and the platform. One recurring theme in reviews: the data is excellent for analytics and segmentation, but extracting simple contact lists for outreach campaigns can feel like using a sledgehammer for a thumbtack.

It's worth being clear about what OneKey is not: it's not a quick-start contact database. You don't sign up on Tuesday and pull a list on Wednesday. Implementation timelines for new IQVIA customers can stretch weeks or months, depending on the scope of data access, integration requirements, and internal approval processes. That's standard for enterprise data platforms, but it's a real factor for teams that need data quickly. If you have a campaign launching in three weeks and don't already have an IQVIA contract in place, you're unlikely to have data in hand by launch day.

Pricing and Contracts

IQVIA does not publish pricing for OneKey or any of its other products. This is standard practice for enterprise data vendors that customize pricing based on data volume, geographic scope, use case, and contract length. You won't find a pricing page on iqvia.com. The process starts with a sales conversation, typically followed by a needs assessment, a custom proposal, and procurement review.

Based on industry reports, published case studies, and feedback from teams who've gone through the procurement process, OneKey contracts typically start in the $50,000 to $200,000+ per year range. The exact figure depends on how many data fields you need access to, how many markets you're covering, whether you're licensing prescribing data alongside the contact records, and whether you're also using IQVIA's analytics or CRM platforms. Teams that bundle multiple IQVIA products often land at the higher end of that range, sometimes significantly above it.

Contracts are annual, and multi-year commitments are common. Some customers report that IQVIA offers better per-record pricing on multi-year deals, but that also means you're locked in for 24 to 36 months. Exiting early typically isn't an option without paying out the remainder of the contract. For teams whose data needs might shift, or companies that are still figuring out their commercial model, that's a substantial bet.

Implementation costs can add to the total. If you need custom integrations with your existing CRM or data warehouse, expect professional services fees on top of the license. Several G2 reviewers mention that the total cost of ownership exceeded their initial expectations once implementation, training, and ongoing support were factored in. One reviewer noted that the integration with their Salesforce instance alone took several weeks and required both internal IT resources and IQVIA professional services.

For a large pharma commercial team with a seven-figure data budget, this pricing can be justified by the prescribing analytics alone. The ROI calculation is straightforward when prescribing data directly informs territory optimization and call planning for a billion-dollar drug. For a 15-person medical device sales team or a healthcare marketing agency with 20 clients, the math often doesn't work. You end up paying for global coverage when you only sell in the U.S., prescribing analytics when you're selling devices not drugs, and platform complexity when you just need a clean CSV.

Where IQVIA Falls Short for Provider Contact Data Buyers

You're paying for capabilities you won't use. IQVIA's pricing reflects the full breadth of their data and analytics ecosystem. If all you need is NPI-verified contact information for healthcare providers in a specific specialty and geography, you're effectively subsidizing prescribing analytics, global HCP coverage, and clinical trial infrastructure you'll never touch. That overhead shows up in your invoice. A healthcare marketing agency that needs 5,000 dermatologist emails in California shouldn't need to pay the same rate as a pharma company analyzing national prescribing trends.

Implementation timelines aren't built for speed. Multiple G2 reviewers describe onboarding processes that took weeks or longer. Enterprise procurement, legal review, data access provisioning, and platform training all add up. If your team needs provider records for a campaign launching next month, IQVIA's timeline may not align with yours. For agencies that serve multiple healthcare clients with different timelines, the lag between signing a contract and pulling your first record can be a real operational problem.

The platform assumes enterprise-level resources. Getting full value from IQVIA often requires a dedicated team or at least a point person who understands the platform, manages the vendor relationship, and translates the data into actionable outputs for sales and marketing. Smaller teams frequently report feeling overwhelmed by the platform's complexity, according to G2 reviews. If your company has 50 employees and no data ops function, you may find yourself paying for a platform that sits underutilized because nobody has time to learn it properly.

Annual contracts create budget inflexibility. If your data needs are seasonal or project-based, a $50,000+ annual commitment creates waste. You can't scale down during slow quarters or pause your subscription between campaigns. The contract runs regardless of how much data you pull. Medical device companies launching in a new territory might need heavy data pulls for three months and then very little for the rest of the year. Under an annual license, you're paying the same rate in month ten as you did in month one.

U.S. provider contact accuracy can vary at the practice level. IQVIA's global strength is in identity resolution and prescribing data, not necessarily in maintaining the freshest email addresses and direct phone numbers for U.S. providers at individual practice locations. Some users on G2 have noted that contact-level data (emails, phone numbers) required supplementation from other sources, even within an active OneKey license. This makes sense when you consider that IQVIA's data sourcing is optimized for analytics and prescribing intelligence, not for maintaining real-time contact accuracy at the practice level. If your primary use case is email outreach or phone-based sales, the contact fields may not be as reliable as you'd expect given the price tag.

The sales process itself can be a barrier. Getting a quote from IQVIA isn't a self-service experience. You'll go through multiple sales calls, a needs assessment, and potentially a proof-of-concept before you see final pricing. For teams that already know exactly what they need (provider contacts filtered by specialty and geography), this process adds time without adding clarity. Some buyers report that the entire procurement cycle, from first call to signed contract, takes two to three months.